How to get a real read on your heart risk when your lipid panel looks fine
If your standard lipid panel looks fine but you want a real read on your heart risk, the markers to add are Apo B, Lp(a) and hs-CRP, none of which are part of a routine lipid panel, and each of which can be elevated while your cholesterol numbers look unremarkable.
A standard BC lipid profile gives you total cholesterol, HDL, non-HDL, LDL-C and triglycerides. That's a reasonable first pass, but LDL-C estimates how much cholesterol you're carrying rather than counting the particles carrying it, and it says nothing about inherited risk or inflammation.
What a standard panel misses
| Marker | What it adds | Why the standard panel misses it |
|---|---|---|
| Apo B | A direct count of atherogenic particles | LDL-C estimates cholesterol content, not particle number |
| Lp(a) | Inherited risk, largely genetic | Not on BC's standard requisition at all |
| hs-CRP | Inflammation, a different risk pathway | Not a lipid measure |
The Apo B point is the one worth sitting with. Every atherogenic particle carries exactly one Apo B molecule, so Apo B counts particles directly. Apo B and LDL-C disagree in about 20% of people, most often those with raised triglycerides, type 2 diabetes or obesity, and when they disagree, the particle count is the better read on risk.
Canadian guidelines reflect this: whenever triglycerides are above 1.5 mmol/L, Apo B or non-HDL-C is recommended instead of LDL-C.
On hs-CRP: higher levels do track with more heart attacks and strokes, though a good part of that association is explained by the conventional risk factors it travels with. Canadian guidelines treat hs-CRP of 2.0 mg/L or above as one of the factors that can tip an intermediate-risk person toward statin therapy.
What Numia measures
Numia's Cardiac panel covers Apo B, Lp(a), hs-CRP, a full lipid profile and VLDL in a single draw , the markers that fill in what a routine panel leaves out.
Sources5 references
- Ahmad, M., Sniderman, A. D., & Hegele, R. A. (2023). Apolipoprotein B in cardiovascular risk assessment. CMAJ, 195(33), E1124. https://doi.org/10.1503/cmaj.230048
- Emerging Risk Factors Collaboration. (2010). C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: An individual participant meta-analysis. The Lancet, 375(9709), 132–140. https://doi.org/10.1016/S0140-6736(09)61717-7
- Guidelines and Protocols Advisory Committee. (2021). Appendix C: Lipid testing in primary prevention of cardiovascular disease. BC Guidelines. British Columbia Ministry of Health.
- Katsi, V., Argyriou, N., Fragoulis, C., & Tsioufis, K. (2025). The role of non-HDL cholesterol and apolipoprotein B in cardiovascular disease: A comprehensive review. Journal of Cardiovascular Development and Disease, 12(7), 256. https://doi.org/10.3390/jcdd12070256
- Pearson, G. J., Thanassoulis, G., Anderson, T. J., Barry, A. R., Couture, P., Dayan, N., Francis, G. A., Genest, J., Grégoire, J., Grover, S. A., Gupta, M., Hegele, R. A., Lau, D., Leiter, L. A., Leung, A. A., Lonn, E., Mancini, G. B. J., Manjoo, P., McPherson, R., … Wray, W. (2021). 2021 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults. Canadian Journal of Cardiology, 37(8), 1129–1150. https://doi.org/10.1016/j.cjca.2021.03.016
Last updated August 29, 2026
